Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 6/20 | 0.48 |
| ▸ | NMT2 | O60551 | 5/20 | 0.48 |
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 2/20 | 0.37 |
| ▸ | NPY2R | P49146 | 2/20 | 0.37 |
| ▸ | NPY4R | P50391 | 2/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24119975 | 0.97 | NMT2 (0.46) | NMT1NMT2GLP1RTLR2NOD1 | |
| SCHEMBL20099362 | 0.94 | NMT2 (0.53) | NMT1NMT2GLP1RTLR2NOD1 | |
| SCHEMBL18879491 | 0.92 | GLP1R (0.49) | NMT1NMT2GLP1RTLR2NOD1 | |
| SCHEMBL18513361 | 0.92 | NMT2 (0.40) | NMT1NMT2GLP1RTLR2NOD1 | |
| SCHEMBL22692648 | 0.92 | NMT2 (0.40) | NMT1NMT2GLP1RTLR2NOD1 | |
| SCHEMBL22857340 | 0.91 | NMT2 (0.40) | NMT1NMT2GLP1RTLR2NOD1 | |
| SCHEMBL22692674 | 0.91 | NMT1 (0.52) | NMT1NMT2GLP1RTLR2NOD1 | |
| SCHEMBL20099252 | 0.90 | NMT2 (0.49) | NMT1NMT2GLP1RTLR2NOD1 | |
| SCHEMBL22692608 | 0.89 | NMT2 (0.48) | NMT1NMT2GLP1RTLR2NOD1 | |
| SCHEMBL20016499 | 0.88 | NMT1 (0.50) | NMT1NMT2GLP1RTLR2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357776-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11732265-B2 | Compositions and methods for modulating complement factor B expression | IONIS PHARMACEUTICALS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230057718-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-02-23 | — | — | US | disclosed |
| US-10844379-B2 | Conjugated antisense compounds and their use | IONIS PHARMACEUTICALS, INC. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20200048638-A1 | COMPOSITIONS AND METHODS FOR MODULATING COMPLEMENT FACTOR B EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2020-02-13 | — | — | US | disclosed |
| US-9994855-B2 | Compositions and methods for modulating growth hormone receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170166899-A1 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10844379-B2 | Conjugated antisense compounds and their use | CSGALNACT1, GALNT1, GALNT6 | NMT1 30/4885NMT2 27/4885GLP1R 1460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.